ENSC Ensysce Biosciences, Inc.: Total Company Value-to-Revenue Ratio

Official company branding of Ensysce Biosciences Inc. (ENSC)

Ensysce Biosciences operates within a secure US legal framework, which mitigates external risks. The proprietary PFAB and MPAR systems allow the company to flexibly manage pricing within the safe analgesics niche. The EV/Sales multiple currently stands at -3688.21, which helps assess the business value relative to revenue. This results in the creation of a closed patent perimeter that ties clinics to unique drug activation protocols.

Ensysce (ENSC) EV/Sales Multiple: for the period 11/23/2025 - 11/20/2026

ensysce.com - analytical breakdowns and key metrics (ENSC)

- company stock capitalization data:
Fundamental company valuation:ENSC (Ensysce)
Product sample of Ensysce Biosciences

For Ensysce Biosciences (ENSC), which develops innovative overdose-protected analgesics, the current EV/Sales ratio reflects the enterprise value of the business net of debt relative to annual revenue. This metric measures the value of operating assets regardless of the financing structure, allowing investors to determine whether they are overpaying for the potential of technology commercialization or to identify an undervaluation of capital.